JAMA Study Bolsters Case for High-Sensitivity Troponin Diagnostics

The results could have implications for the future adoption by cardiologists of high-sensitivity troponin assays currently being developed by biotech firms like Singulex and Nanosphere.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.